product name Dexmedetomidine
Description: Dexmedetomidine is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation. Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation.
References: Eur J Pharmacol. 1988 May 20;150(1-2):9-14; Anesthesiology. 1997 Feb;86(2):331-45.
200.28
Formula
C13H16N2
CAS No.
113775-47-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 40 mg/mL (199.7 mM)
Water: 40 mg/mL (199.7 mM)
Ethanol: 40 mg/mL (199.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398699
| In Vitro |
In vitro activity: Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 1988 May 20;150(1-2):9-14; Anesthesiology. 1997 Feb;86(2):331-45. |
Related Posts
product name Dexmedetomidine
Description: Dexmedetomidine is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation. Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation.
References: Eur J Pharmacol. 1988 May 20;150(1-2):9-14; Anesthesiology. 1997 Feb;86(2):331-45.
200.28
Formula
C13H16N2
CAS No.
113775-47-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 40 mg/mL (199.7 mM)
Water: 40 mg/mL (199.7 mM)
Ethanol: 40 mg/mL (199.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19398699
| In Vitro |
In vitro activity: Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 1988 May 20;150(1-2):9-14; Anesthesiology. 1997 Feb;86(2):331-45. |